Esper Peg, Gale Danielle, Muehlbauer Paula
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
Clin J Oncol Nurs. 2007 Oct;11(5):659-66. doi: 10.1188/07.CJON.659-666.
An overwhelming number of new agents, including targeted agents with unique mechanisms of action, are available in oncology practice today. Along with the benefit of new treatments for patients comes the unfamiliarity of associated toxicities and learning the best methods to minimize side effects. One such toxicity has been the spectrum of dermatologic reactions from some of the newer small-molecule inhibitors and monoclonal antibodies. Scientific evidence describing the unique rashes and methodologies to treat various cutaneous toxicities with specific agents is extremely limited. This article reviews the currently available literature related to dermatologic toxicities observed with many newer targeted therapies. Current recommendations for management are based on practices implemented during clinical trials and postmarketing practices. Additional research is needed to further elucidate the most efficacious methods for treating side effects observed with newer targeted therapies.
如今，肿瘤学实践中有大量新药物可供使用，包括具有独特作用机制的靶向药物。新治疗方法给患者带来益处的同时，也伴随着对相关毒性的不熟悉以及摸索将副作用降至最低的最佳方法。其中一种毒性就是一些新型小分子抑制剂和单克隆抗体引起的一系列皮肤反应。描述独特皮疹以及用特定药物治疗各种皮肤毒性的方法的科学证据极其有限。本文综述了目前与许多新型靶向治疗所观察到的皮肤毒性相关的文献。当前的管理建议基于临床试验和上市后实践中采用的做法。还需要进一步研究，以进一步阐明治疗新型靶向治疗所观察到的副作用的最有效方法。
